CURATIS N AG (CURN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CURATIS N AG (CURN) has a cash flow conversion efficiency ratio of -0.024x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-1.05 Million ≈ $-1.33 Million USD) by net assets (CHF44.56 Million ≈ $56.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CURATIS N AG - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how CURATIS N AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CURATIS N AG (CURN) financial obligations for a breakdown of total debt and financial obligations.
CURATIS N AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CURATIS N AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CDON AB
ST:CDON
|
-0.042x |
|
Q.BEYOND AG NA O.N. KONV.
XETRA:QBY0
|
0.035x |
|
Intertek Group PLC
LSE:ITRK
|
0.124x |
|
Bathurst Resources Ltd
F:B0R
|
0.017x |
|
Oceanic Iron Ore Corp
V:FEO
|
0.004x |
|
Doosan Fuel Cell Co. Ltd. Pfd. Series 1
KO:33626K
|
-0.043x |
|
Yunsa Yunlu Sanayi ve Ticaret AS
IS:YUNSA
|
0.030x |
|
Alithya Group Inc
NASDAQ:ALYAF
|
0.152x |
Annual Cash Flow Conversion Efficiency for CURATIS N AG (2002–2024)
The table below shows the annual cash flow conversion efficiency of CURATIS N AG from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see market value of CURATIS N AG.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF45.60 Million ≈ $57.65 Million |
CHF-825.00K ≈ $-1.04 Million |
-0.018x | -100.30% |
| 2023-12-31 | CHF-312.00K ≈ $-394.45K |
CHF-1.89 Million ≈ $-2.38 Million |
6.042x | +976.84% |
| 2022-12-31 | CHF6.75 Million ≈ $8.54 Million |
CHF-4.65 Million ≈ $-5.88 Million |
-0.689x | -176.77% |
| 2021-12-31 | CHF-400.00K ≈ $-505.71K |
CHF-359.00K ≈ $-453.87K |
0.898x | -38.98% |
| 2020-12-31 | CHF-257.00K ≈ $-324.92K |
CHF-378.00K ≈ $-477.89K |
1.471x | +22.64% |
| 2019-12-31 | CHF-552.00K ≈ $-697.88K |
CHF-662.00K ≈ $-836.95K |
1.199x | +160.36% |
| 2018-12-31 | CHF377.00K ≈ $476.63K |
CHF-749.00K ≈ $-946.94K |
-1.987x | -7596.73% |
| 2017-12-31 | CHF4.68 Million ≈ $5.92 Million |
CHF124.00K ≈ $156.77K |
0.027x | +273.50% |
| 2016-12-31 | CHF5.04 Million ≈ $6.37 Million |
CHF-77.00K ≈ $-97.35K |
-0.015x | +23.75% |
| 2015-12-31 | CHF6.24 Million ≈ $7.89 Million |
CHF-125.00K ≈ $-158.03K |
-0.020x | -34.08% |
| 2014-12-31 | CHF7.90 Million ≈ $9.99 Million |
CHF-118.00K ≈ $-149.18K |
-0.015x | +92.26% |
| 2013-12-31 | CHF8.71 Million ≈ $11.01 Million |
CHF-1.68 Million ≈ $-2.12 Million |
-0.193x | -445.52% |
| 2012-12-31 | CHF11.60 Million ≈ $14.67 Million |
CHF648.00K ≈ $819.25K |
0.056x | +32.82% |
| 2011-12-31 | CHF7.16 Million ≈ $9.05 Million |
CHF301.00K ≈ $380.55K |
0.042x | -82.42% |
| 2010-12-31 | CHF6.98 Million ≈ $8.82 Million |
CHF1.67 Million ≈ $2.11 Million |
0.239x | +41.54% |
| 2009-12-31 | CHF5.88 Million ≈ $7.44 Million |
CHF994.00K ≈ $1.26 Million |
0.169x | +105.69% |
| 2008-12-31 | CHF1.64 Million ≈ $2.08 Million |
CHF-4.88 Million ≈ $-6.16 Million |
-2.968x | +90.51% |
| 2007-12-31 | CHF227.00K ≈ $286.99K |
CHF-7.10 Million ≈ $-8.98 Million |
-31.282x | -10014.42% |
| 2006-12-31 | CHF9.30 Million ≈ $11.76 Million |
CHF-2.88 Million ≈ $-3.64 Million |
-0.309x | -27.63% |
| 2005-12-31 | CHF21.67 Million ≈ $27.40 Million |
CHF-5.25 Million ≈ $-6.64 Million |
-0.242x | -801.22% |
| 2004-12-31 | CHF37.30 Million ≈ $47.16 Million |
CHF1.29 Million ≈ $1.63 Million |
0.035x | +188.13% |
| 2003-12-31 | CHF49.83 Million ≈ $63.00 Million |
CHF-1.95 Million ≈ $-2.47 Million |
-0.039x | +89.09% |
| 2002-12-31 | CHF55.33 Million ≈ $69.96 Million |
CHF-19.88 Million ≈ $-25.13 Million |
-0.359x | -- |
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more